Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conteltinib in ALK-positive NSCLC
NCT02695550Phase 1Unknown
- Sponsor
- Centaurus Biopharma Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of conteltinib in non-small cell lung cancer (NSCLC), sponsored by Centaurus Biopharma Co., Ltd. Primary endpoints: Incidence rate of dose limiting toxicities at 28 days and Frequency of adverse events/serious adverse events up to 24 months. Status: unknown.
02
Drugs
conteltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02695550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695550.